Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Recent advances in triple negative breast cancer: the immunotherapy era

(2019) Antonio Marra et al.   BMC Medicine

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

(2019) Javier Cortés et al.   Future Oncology

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

Immune checkpoints in the tumor microenvironment

(2019) Salman M. Toor et al.   SEMINARS IN CANCER BIOLOGY

Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression

(2019) Reem Saleh et al.   SEMINARS IN CANCER BIOLOGY

Treg-mediated acquired resistance to immune checkpoint inhibitors

(2019) Reem Saleh et al.   CANCER LETTERS

Mechanisms of immune evasion in breast cancer

(2018) Joshua P. Bates et al.   BMC CANCER

Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells

(2018) Varun Sasidharan Nair et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Expression of PD-1 on CD4+ Tumor-Infiltrating Lymphocytes in Tumor Microenvironment Associated with Pathological Characteristics of Breast Cancer

(2018) Yan-Jie Zhao et al.   Journal of Immunology Research

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Programmed Cell Death Protein-1 Predicts the Recurrence of Breast Cancer in Patients Subjected to Radiotherapy After Breast-Preserving Surgery

(2018) Ruyi Huang et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

The clinical promise of immunotherapy in triple-negative breast cancer

(2018) Praveen Vikas et al.   Cancer Management and Research

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells

(2017) Varun Sasidharan Nair et al.   IMMUNOLOGY AND CELL BIOLOGY

Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer

(2017) Azharuddin Sajid Syed Khaja et al.   Frontiers in Immunology

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

(2016) Toni K. Choueiri et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

(2016) Kankana Bardhan et al.   Frontiers in Immunology

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

(2016) Ruea-Yea Huang et al.   OncoImmunology

Helios—controller of Treg stability and function

(2016) Claire Chougnet et al.   Translational Cancer Research

Helios Controls a Limited Subset of Regulatory T Cell Functions

(2015) Mathew Sebastian et al.   JOURNAL OF IMMUNOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP

(2015) Eyad Elkord et al.   Oncotarget

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

(2015) Annie A Wu et al.   OncoImmunology

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) H. Wimberly et al.   Cancer Immunology Research

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

(2010) C. Camisaschi et al.   JOURNAL OF IMMUNOLOGY

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells

(2009) Wenshi Wang et al.   INTERNATIONAL IMMUNOLOGY

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

(2009) Maciej Kmieciak et al.   Journal of Translational Medicine

FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

(2008) Hazem Ghebeh et al.   BMC CANCER